Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


First published on March 9, 2009
This version was published on January 1, 2009
Neuro Oncol 2009 11(3):318-322; DOI:10.1215/15228517-2008-103
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/3/318    most recent
15228517-2008-103v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pulido, J. S.
Right arrow Articles by O'Neill, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Clinical Investigations

Racial differences in primary central nervous system lymphoma incidence and survival rates

Jose S. Pulido, Robert A. Vierkant, Janet E. Olson, Lauren Abrey, David Schiff and Brian Patrick O'Neill

Departments of Ophthalmology, Health Sciences Research, and Neurology, Mayo Clinic and Foundation and the Mayo Clinic Cancer Center, Rochester, MN (J.S.P., R.A.V., J.E.O., B.P.O.); Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY (L.A.); Departments of Neurology and Neurosurgery, University of Virginia Health System, Charlottesville, VA (D.S.); USA

Address correspondence to Jose S. Pulido, Mayo Clinic, Department of Ophthalmology, 200 First St., SW, Rochester, MN 55905, USA (pulido.jose{at}mayo.edu).

To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20–49 years vs. 50 or above) and race (White, Black, Asian/Pacific Islander [A/PI], American Indian/Alaskan Native [AI/AN]). Incidence of PCNSL and survival were calculated by SEER*Stat software. The incidence rates were 0.94 per 100,000 per year (95% confidence interval [CI] 0.90–0.98) for Whites, 1.10 (95% CI 0.98–1.22) for Blacks, 0.51 (95% CI 0.28–0.74) for AI/AN, and 0.64 (95% CI 0.56–0.72) for A/PI. In patients aged 20–49 years the rates were 0.72 (95% CI 0.68–0.76) for Whites, 1.43 (95% CI 1.27–1.59) for Blacks, 0.58 (95% CI 0.30–0.86) for AI/AN, and 0.21 (CI 0.15–0.27) for A/PI. In patients over 49 years, the rates were 1.30 (95% CI 1.22–1.38) for Whites, 0.56 (95% CI 0.40–0.72) for Blacks, 0.34 (95% CI 0–0.70) for AI/AN, and 1.31 (95% CI 1.00–1.53) for A/PI. PCNSL incidence for ages 20–49 years for Black patients was twice that for Whites. Incidence for ages over 49 years for Whites was twice that for Blacks. Survival at 12 months, 24 months, and 60 months was higher among Whites than Blacks. Research is needed to determine the origin of these differences.

Key Words: epidemiology • race


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2009 by Society for Neuro-Oncology